A Phase 2 interventional study of Pembrolizumab/Vibostolimab coformulation and Docetaxel in Metastatic Non Small Cell Lung Cancer, sponsored by Merck Sharp & Dohme LLC. Completed at 95 sites in 20 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-15.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 198 studies testing docetaxel in Carcinoma, Non-Small-Cell Lung — 13 open to participants now, 20 under way, 3 of them phase 3. Docetaxel · Carcinoma, Non-Small-Cell Lung.
Among the 198 studies testing docetaxel in Carcinoma, Non-Small-Cell Lung, this one is the 27th largest by enrollment of the 188 interventional ones that give a count, is one of 4 that started in 2021, is one of 125 in phase 2, and was the 178th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →13 of the 198 studies testing docetaxel in Carcinoma, Non-Small-Cell Lung are open now, in 8 countries. Recruiting first, the newest first:
Tianjin Medical University Cancer Institute and Hospital · Sites in China
Ages 18+
Second Xiangya Hospital of Central South University · Sites in China
Ages 18–75
Tianjin Medical University Cancer Institute and Hospital · Sites in China
Ages 18–75
CatalYm GmbH · Sites in United States, Germany, Italy and 4 more countries
Ages 18+
Akeso · Sites in China
Ages 18–75
By country, each count listing its studies:
Docetaxel: first FDA approval 1996 (TAXOTERE), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →
Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
198 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 36 · Phase 2 143 · Phase 3 32 · Phase 4 2
First in 1996; this study’s year is marked. 4 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 255 is above the median of 62 across 6,023 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 50 across the 188 interventional studies. Of the 147 that completed or were terminated, 51 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
49 of 198 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
91 studies in Carcinoma, Non-Small-Cell Lung by Merck & Co., Inc: 14 open now, 26 under way, 18 of them phase 3. Of 65 finished, 49 (75%) have results posted.
Among the 91 studies in Carcinoma, Non-Small-Cell Lung by Merck & Co., Inc, this one is the 37th largest by enrollment of the 88 interventional ones that give a count, is one of 4 that started in 2021, is one of 24 in phase 2, and was the 63rd registered.
Merck & Co., Inc’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2000.
7 of the studies testing docetaxel in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06382129Phase 3Sichuan Baili Pharmaceutical Co., Ltd.A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer(PANKU-Lung02) | 2026-12 |
| NCT06928389Phase 3AkesoIvonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer | 2027-05 |
| NCT02889666Shanghai Jiao Tong University School of MedicineA Randomised Trial of Chemotherapy Plus Surgery for Recurrent Non-Small Cell Lung Cancer | 2026-12 |
| NCT07330050Tianjin Medical University Cancer Institute and HospitalWAST Cell-Docetaxel Combination Therapy in PD-1 Inhibitor-Resistant Advanced NSCLC | 2026-12-31 |
| NCT06879717iOncturaA Study of Roginolisib (IOA-244) in Combination With Dostarlimab With or Without Docetaxel in Metastatic Non Small-cell Lung Cancer (NSCLC) Patients | 2027-01 |
Add all 7 to your calendar (.ics) → With an account.
Among the 198 studies testing docetaxel in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 91 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to compare pembrolizumab/vibostolimab coformulation (MK-7684A) plus docetaxel or pembrolizumab/vibostolimab coformulation to normal saline placebo plus docetaxel. Participants with metastatic non-small cell lung cancer (NSCLC) and progressive disease (PD) after platinum doublet chemotherapy and treatment with one prior anti- programmed cell death 1 (PD-1)/ programmed cell death ligand 1(PD-L1) monoclonal antibody (mAb). MK-7684A is a coformulation product of pembrolizumab/vibostolimab. The dual primary hypotheses of the study are pembrolizumab/vibostolimab coformulation plus docetaxel and pembrolizumab/vibostolimab coformulation is superior to normal saline placebo plus docetaxel with respect to progression free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by blinded independent central review (BICR).
Participants may receive additional 17 cycles of pembrolizumab/vibostolimab (each cycle length = 21 days) for an additional 1 year of treatment as second course phase at investigator's discretion.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Has progressive disease (PD) on treatment with one prior anti-programmed cell death 1 ()/ programmed cell death ligand 1 (PD-L1) monoclonal antibody (mAb) administered either as monotherapy or in combination with other checkpoint inhibitors or other therapies
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous (IV) infusion once every 3 weeks (Q3W) for up to 35 cycles up to approximately 2 years plus docetaxel 75 mg/m\^2 via IV infusion Q3W. Each cycle will be 21 days.
Biological: Pembrolizumab/Vibostolimab coformulation · Drug: Docetaxel
Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion Q3W for up to 35 cycles up to approximately 2 years. Each cycle will be 21 days.
Biological: Pembrolizumab/Vibostolimab coformulation
Participants receive normal saline placebo via IV infusion Q3W for up to 35 cycles up to approximately 2 years plus docetaxel 75 mg/m\^2 IV infusion Q3W. Each cycle will be 21 days.
Drug: Docetaxel · Drug: Placebo
Drug page: Vibostolimab/Pembrolizumab MK-7684A
Pembrolizumab 200 mg + vibostolimab 200 mg/20 mL vial IV infusion Q3W up to approximately 2 years.
Also known as: MK-7684A
Docetaxel 75 mg\^m2 IV infusion Q3W until discontinuation due to progressive disease or unacceptable toxicity. Docetaxel will serve as part of an experimental treatment in Arm 1, and as an active comparator in Arm 3.
Also known as: Taxotere
Normal saline IV infusion Q3W up to approximately 2 years
This study also gives Pembrolizumab. No intervention listed here names it: that was found by reading the record.
Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR) Assessment
PFS is defined as the time from randomization to the first documented disease progression (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by BICR is presented.
Time frame: Up to approximately 21 months
Objective Response Rate (ORR) Per RECIST 1.1 by BICR Assessment
ORR is defined as the percentage of participants who have a confirmed complete response (CR: Disappearance of all target lesions) or a partial response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. The percentage of participants who experience a CR or PR as assessed by BICR based on RECIST 1.1 is presented.
Time frame: Up to approximately 21 months
Overall Survival (OS)
OS is defined as the time from randomization to the date of death due to any cause.
Time frame: Up to approximately 21 months
Duration of Response (DOR) Per RECIST 1.1 by BICR Assessment
For participants who demonstrate a confirmed CR (Disappearance of all target lesions) or confirmed PR (At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until disease progression (PD) or death. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered PD. The DOR as assessed by BICR is presented.
Time frame: Up to approximately 21 months
Number of Participants Who Experienced an Adverse Event (AE)
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experienced an AE is reported here.
Time frame: Up to approximately 39 months
Number of Participants Who Discontinued Study Treatment Due to an AE
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinued study treatment due to an AE is reported here.
Time frame: Up to approximately 27 months
| Milestone | Arm 1: Pembrolizumab/Vibostolimab Coformulation + Docetaxel | Arm 2: Pembrolizumab/Vibostolimab Coformulation | Arm 3: Placebo + Docetaxel |
|---|---|---|---|
| Started | 87 | 83 | 85 |
| Treated | 85 | 83 | 83 |
| Completed | 0 | 0 | 0 |
| Not completed | 87 | 83 | 85 |
| Withdrew: Death | 72 | 69 | 76 |
| Withdrew: Lost to follow-up | 1 | 0 | 1 |
| Withdrew: Withdrawal by subject | 2 | 2 | 1 |
| Withdrew: Sponsor decision | 12 | 12 | 7 |
PFS is defined as the time from randomization to the first documented disease progression (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by BICR is presented.
| Months | Arm 1: Pembrolizumab/Vibostolimab Coformulation + Docetaxel | Arm 2: Pembrolizumab/Vibostolimab Coformulation | Arm 3: Placebo + Docetaxel |
|---|---|---|---|
| Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR) Assessment | 5.6 (3.9 to 6.8) | 2.7 (1.8 to 4.0) | 3.2 (2.8 to 5.7) |
ORR is defined as the percentage of participants who have a confirmed complete response (CR: Disappearance of all target lesions) or a partial response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. The percentage of participants who experience a CR or PR as assessed by BICR based on RECIST 1.1 is presented.
| Percentage of participants | Arm 1: Pembrolizumab/Vibostolimab Coformulation + Docetaxel | Arm 2: Pembrolizumab/Vibostolimab Coformulation | Arm 3: Placebo + Docetaxel |
|---|---|---|---|
| Objective Response Rate (ORR) Per RECIST 1.1 by BICR Assessment | 29.9 (20.5 to 40.6) | 6.0 (2.0 to 13.5) | 15.3 (8.4 to 24.7) |
OS is defined as the time from randomization to the date of death due to any cause.
| Months | Arm 1: Pembrolizumab/Vibostolimab Coformulation + Docetaxel | Arm 2: Pembrolizumab/Vibostolimab Coformulation | Arm 3: Placebo + Docetaxel |
|---|---|---|---|
| Overall Survival (OS) | 10.2 (8.6 to 14.9) | 7.5 (5.2 to 13.4) | 8.8 (6.4 to 11.1) |
For participants who demonstrate a confirmed CR (Disappearance of all target lesions) or confirmed PR (At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until disease progression (PD) or death. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered PD. The DOR as assessed by BICR is presented.
| Months | Arm 1: Pembrolizumab/Vibostolimab Coformulation + Docetaxel | Arm 2: Pembrolizumab/Vibostolimab Coformulation | Arm 3: Placebo + Docetaxel |
|---|---|---|---|
| Duration of Response (DOR) Per RECIST 1.1 by BICR Assessment | 6.5 (5.3 to 10.7) | NA (2.8 to NA) | NA (3.0 to NA) |
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experienced an AE is reported here.
| Participants | Arm 1: Pembrolizumab/Vibostolimab Coformulation + Docetaxel | Arm 2: Pembrolizumab/Vibostolimab Coformulation | Arm 3: Placebo + Docetaxel |
|---|---|---|---|
| Number of Participants Who Experienced an Adverse Event (AE) | 85 | 76 | 82 |
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinued study treatment due to an AE is reported here.
| Participants | Arm 1: Pembrolizumab/Vibostolimab Coformulation + Docetaxel | Arm 2: Pembrolizumab/Vibostolimab Coformulation | Arm 3: Placebo + Docetaxel |
|---|---|---|---|
| Number of Participants Who Discontinued Study Treatment Due to an AE | 42 | 12 | 24 |
Collected over Up to approximately 39 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pembrolizumab/Vibostolimab Coformulation + Docetaxel | 74/87 (85.1%) | 48/85 (56.5%) | 83/85 (97.6%) |
| Pembrolizumab/Vibostolimab Coformulation | 70/83 (84.3%) | 26/83 (31.3%) | 67/83 (80.7%) |
| Placebo + Docetaxel | 77/85 (90.6%) | 37/83 (44.6%) | 76/83 (91.6%) |
| Event | Pembrolizumab/Vibostolimab Coformulation + Docetaxel | Pembrolizumab/Vibostolimab Coformulation | Placebo + Docetaxel |
|---|---|---|---|
| PneumoniaInfections and infestations | 7/85 | 3/83 | 10/83 |
| Febrile neutropeniaBlood and lymphatic system disorders | 3/85 | 0/83 | 3/83 |
| AnaemiaBlood and lymphatic system disorders | 3/85 | 1/83 | 2/83 |
| DiarrhoeaGastrointestinal disorders | 3/85 | 1/83 | 2/83 |
| COVID-19Infections and infestations | 3/85 | 1/83 | 1/83 |
| Septic shockInfections and infestations | 3/85 | 0/83 | 0/83 |
| Hip fractureInjury, poisoning and procedural complications | 3/85 | 0/83 | 0/83 |
| DeathGeneral disorders | 1/85 | 1/83 | 2/83 |
| COVID-19 pneumoniaInfections and infestations | 0/85 | 2/83 | 0/83 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 1/85 | 1/83 | 2/83 |
| Event | Pembrolizumab/Vibostolimab Coformulation + Docetaxel | Pembrolizumab/Vibostolimab Coformulation | Placebo + Docetaxel |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 31/85 | 10/83 | 23/83 |
| PruritusSkin and subcutaneous tissue disorders | 31/85 | 17/83 | 4/83 |
| AnaemiaBlood and lymphatic system disorders | 30/85 | 12/83 | 28/83 |
| AstheniaGeneral disorders | 26/85 | 15/83 | 24/83 |
| FatigueGeneral disorders | 26/85 | 10/83 | 23/83 |
| NauseaGastrointestinal disorders | 24/85 | 11/83 | 22/83 |
| AlopeciaSkin and subcutaneous tissue disorders | 24/85 | 2/83 | 20/83 |
| RashSkin and subcutaneous tissue disorders | 22/85 | 15/83 | 7/83 |
| Decreased appetiteMetabolism and nutrition disorders | 21/85 | 11/83 | 19/83 |
| ConstipationGastrointestinal disorders | 20/85 | 6/83 | 9/83 |
| Age, Continuous(Years) | Arm 1: Pembrolizumab/Vibostolimab Coformulation + Docetaxel | Arm 2: Pembrolizumab/Vibostolimab Coformulation | Arm 3: Placebo + Docetaxel | Total |
|---|---|---|---|---|
| Mean | 64.7 ± 8.8 | 66.0 ± 7.4 | 65.8 ± 8.0 | 65.5 ± 8.1 |
| Sex: Female, Male(Participants) | Arm 1: Pembrolizumab/Vibostolimab Coformulation + Docetaxel | Arm 2: Pembrolizumab/Vibostolimab Coformulation | Arm 3: Placebo + Docetaxel | Total |
|---|---|---|---|---|
| Female | 27 | 23 | 24 | 74 |
| Male | 60 | 60 | 61 | 181 |
| Ethnicity (NIH/OMB)(Participants) | Arm 1: Pembrolizumab/Vibostolimab Coformulation + Docetaxel | Arm 2: Pembrolizumab/Vibostolimab Coformulation | Arm 3: Placebo + Docetaxel | Total |
|---|---|---|---|---|
| Hispanic or Latino | 12 | 9 | 6 | 27 |
| Not Hispanic or Latino | 62 | 68 | 65 | 195 |
| Unknown or Not Reported | 13 | 6 | 14 | 33 |
| Race (NIH/OMB)(Participants) | Arm 1: Pembrolizumab/Vibostolimab Coformulation + Docetaxel | Arm 2: Pembrolizumab/Vibostolimab Coformulation | Arm 3: Placebo + Docetaxel | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 11 | 14 | 10 | 35 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 0 | 1 |
| Black or African American | 0 | 1 | 1 | 2 |
| White | 62 | 63 | 60 | 185 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 13 | 5 | 14 | 32 |
| Programmed Cell Death Ligand 1 (PD-L1) Status at Baseline(Participants) | Arm 1: Pembrolizumab/Vibostolimab Coformulation + Docetaxel | Arm 2: Pembrolizumab/Vibostolimab Coformulation | Arm 3: Placebo + Docetaxel | Total |
|---|---|---|---|---|
| Tumor proportion score (TPS) ≥50% | 15 | 14 | 13 | 42 |
| TPS 1-49% | 34 | 19 | 35 | 88 |
| TPS <1% | 37 | 45 | 34 | 116 |
| Unknown (Not evaluable due to <100 viable tumor cells) | 1 | 5 | 3 | 9 |
| Predominant Tumor Histology(Participants) | Arm 1: Pembrolizumab/Vibostolimab Coformulation + Docetaxel | Arm 2: Pembrolizumab/Vibostolimab Coformulation | Arm 3: Placebo + Docetaxel | Total |
|---|---|---|---|---|
| Squamous | 26 | 20 | 34 | 80 |
| Non-squamous | 61 | 63 | 51 | 175 |
| Prior Lines of Therapy(Participants) | Arm 1: Pembrolizumab/Vibostolimab Coformulation + Docetaxel | Arm 2: Pembrolizumab/Vibostolimab Coformulation | Arm 3: Placebo + Docetaxel | Total |
|---|---|---|---|---|
| 1 | 58 | 49 | 52 | 159 |
| 2 | 25 | 28 | 26 | 79 |
| 3 | 1 | 4 | 7 | 12 |
| 4 | 1 | 2 | 0 | 3 |
| ≥5 | 2 | 0 | 0 | 2 |
| Sequence of Prior Anti-Programmed Cell Death Receptor 1 (PD-1)/PD-L1(Participants) | Arm 1: Pembrolizumab/Vibostolimab Coformulation + Docetaxel | Arm 2: Pembrolizumab/Vibostolimab Coformulation | Arm 3: Placebo + Docetaxel | Total |
|---|---|---|---|---|
| Immediate Prior Therapy | 72 | 70 | 72 | 214 |
| Not the Immediate Prior Therapy | 15 | 13 | 13 | 41 |
1 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Apr 2021 to primary completion in Jan 2023, 21 months.
Results were first posted in Apr 2024, 1 year 2 months after primary completion.
Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's 21 months is below that.
Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Vibostolimab/Pembrolizumab MK-7684A · Docetaxel
Carcinoma, Non-Small-Cell Lung →